On 12 October 2022, the application filed by Beijing Sunho Pharmaceutical Co., Ltd. (430017.OC, “Beijing Sunho”) for its public offering and listing on Beijing Stock Exchange was passed and approved by the Listing Committee of Beijing Stock Exchange. 

The company is mainly engaged in the research and development, production and sales of pharmaceutical formulations, and builds a sharing platform to provide CMC/CMO services for pharmaceutical formulation manufacturers and innovative drug enterprises while industrializing its own products, and now its business radiates nationwide.

Grandall Shanghai Office has been retained as the issuer’s legal advisor with SHI Nianqing, WU Wenhao, LIANG Xiaowei and CHEN Ying as key lawyers serving the case.